Compare DHX & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DHX | AGEN |
|---|---|---|
| Founded | 1991 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.3M | 147.4M |
| IPO Year | 2007 | 1999 |
| Metric | DHX | AGEN |
|---|---|---|
| Price | $3.97 | $5.62 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $6.25 | ★ $14.50 |
| AVG Volume (30 Days) | 155.6K | ★ 7.4M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | 0.04 | ★ 1.02 |
| Revenue | ★ $127,826,000.00 | $42,877,086.00 |
| Revenue This Year | N/A | $107.63 |
| Revenue Next Year | $3.52 | N/A |
| P/E Ratio | $97.75 | ★ $5.92 |
| Revenue Growth | N/A | ★ 89.95 |
| 52 Week Low | $1.44 | $2.71 |
| 52 Week High | $4.32 | $8.70 |
| Indicator | DHX | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 59.01 | 75.17 |
| Support Level | $3.49 | $2.96 |
| Resistance Level | $4.00 | N/A |
| Average True Range (ATR) | 0.25 | 0.54 |
| MACD | 0.01 | 0.28 |
| Stochastic Oscillator | 59.27 | 47.70 |
DHI Group Inc is a provider of software products, online tools, and services that deliver career marketplaces to candidates and employers in the United States. The company operates through two reportable segments: ClearanceJobs and Dice. Its brands enable recruiters and hiring managers to search, match, and connect with skilled technologists, particularly in technology and active government security clearance, while professionals find job opportunities, job advice, and personalized data. ClearanceJobs connects security-cleared professionals with employers in a secure environment and supports engagement through messaging and live video. Dice, which generates maximum revenue, is a destination for technology and engineering talent, offering job postings across a range of technology roles.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.